JP2019515881A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515881A5 JP2019515881A5 JP2018549315A JP2018549315A JP2019515881A5 JP 2019515881 A5 JP2019515881 A5 JP 2019515881A5 JP 2018549315 A JP2018549315 A JP 2018549315A JP 2018549315 A JP2018549315 A JP 2018549315A JP 2019515881 A5 JP2019515881 A5 JP 2019515881A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- alanine
- oxidase
- amino acids
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 12
- 102000004316 Oxidoreductases Human genes 0.000 claims 12
- 108090000854 Oxidoreductases Proteins 0.000 claims 12
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 10
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 10
- 229940024606 amino acid Drugs 0.000 claims 10
- 235000001014 amino acid Nutrition 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 8
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 8
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 8
- 208000035143 Bacterial infection Diseases 0.000 claims 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 7
- 208000022362 bacterial infectious disease Diseases 0.000 claims 7
- 239000004471 Glycine Substances 0.000 claims 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 6
- 229930182821 L-proline Natural products 0.000 claims 6
- 102000003896 Myeloperoxidases Human genes 0.000 claims 6
- 108090000235 Myeloperoxidases Proteins 0.000 claims 6
- 229960003767 alanine Drugs 0.000 claims 6
- 150000002978 peroxides Chemical class 0.000 claims 6
- 229960002429 proline Drugs 0.000 claims 6
- 239000000758 substrate Substances 0.000 claims 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 5
- WWISPHBAYBECQZ-IMJSIDKUSA-N (3s,6s)-3,6-dimethylpiperazine-2,5-dione Chemical compound C[C@@H]1NC(=O)[C@H](C)NC1=O WWISPHBAYBECQZ-IMJSIDKUSA-N 0.000 claims 4
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims 4
- OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical compound CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 claims 4
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 claims 4
- 229930182845 D-isoleucine Natural products 0.000 claims 4
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims 4
- 229930182819 D-leucine Natural products 0.000 claims 4
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 4
- 229930182832 D-phenylalanine Natural products 0.000 claims 4
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 claims 4
- 229930182822 D-threonine Natural products 0.000 claims 4
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims 4
- 229930182831 D-valine Natural products 0.000 claims 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 4
- 229930182816 L-glutamine Natural products 0.000 claims 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 4
- 239000004395 L-leucine Substances 0.000 claims 4
- 235000019454 L-leucine Nutrition 0.000 claims 4
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- 125000005907 alkyl ester group Chemical group 0.000 claims 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 4
- 239000002158 endotoxin Substances 0.000 claims 4
- 229960002989 glutamic acid Drugs 0.000 claims 4
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycine anhydride Natural products [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims 4
- 229960002885 histidine Drugs 0.000 claims 4
- 229960003136 leucine Drugs 0.000 claims 4
- 229960003104 ornithine Drugs 0.000 claims 4
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229960001153 serine Drugs 0.000 claims 4
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims 4
- 229960003080 taurine Drugs 0.000 claims 4
- 229960002898 threonine Drugs 0.000 claims 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 4
- 229960004441 tyrosine Drugs 0.000 claims 4
- 229960004295 valine Drugs 0.000 claims 4
- 229930182844 L-isoleucine Natural products 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 229960000310 isoleucine Drugs 0.000 claims 3
- 229920006008 lipopolysaccharide Polymers 0.000 claims 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 3
- SKWCZPYWFRTSDD-HSHFZTNMSA-N (2r)-2,3-diaminopropanoic acid;hydrochloride Chemical compound Cl.NC[C@@H](N)C(O)=O SKWCZPYWFRTSDD-HSHFZTNMSA-N 0.000 claims 2
- SKWCZPYWFRTSDD-DKWTVANSSA-N (2s)-2,3-diaminopropanoic acid;hydrochloride Chemical compound Cl.NC[C@H](N)C(O)=O SKWCZPYWFRTSDD-DKWTVANSSA-N 0.000 claims 2
- QCHPKSFMDHPSNR-GSVOUGTGSA-N (R)-3-aminoisobutyric acid Chemical compound [NH3+]C[C@@H](C)C([O-])=O QCHPKSFMDHPSNR-GSVOUGTGSA-N 0.000 claims 2
- MLYMSIKVLAPCAK-LURJTMIESA-N (S)-3-Amino-5-methylhexanoic acid Chemical compound CC(C)C[C@H](N)CC(O)=O MLYMSIKVLAPCAK-LURJTMIESA-N 0.000 claims 2
- QCHPKSFMDHPSNR-VKHMYHEASA-N (S)-3-aminoisobutyric acid Chemical compound [NH3+]C[C@H](C)C([O-])=O QCHPKSFMDHPSNR-VKHMYHEASA-N 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- 108010015776 Glucose oxidase Proteins 0.000 claims 2
- 239000004366 Glucose oxidase Substances 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 229940000635 beta-alanine Drugs 0.000 claims 2
- 230000007893 endotoxin activity Effects 0.000 claims 2
- HSOGVWWWGVFXGF-UHFFFAOYSA-N ethyl n-(2-cyanoacetyl)carbamate Chemical compound CCOC(=O)NC(=O)CC#N HSOGVWWWGVFXGF-UHFFFAOYSA-N 0.000 claims 2
- 229940116332 glucose oxidase Drugs 0.000 claims 2
- 235000019420 glucose oxidase Nutrition 0.000 claims 2
- 208000027096 gram-negative bacterial infections Diseases 0.000 claims 2
- HQZMRJBVCVYVQA-UHFFFAOYSA-N hydron;methyl 2-(methylamino)acetate;chloride Chemical compound Cl.CNCC(=O)OC HQZMRJBVCVYVQA-UHFFFAOYSA-N 0.000 claims 2
- 108700027361 sarcosine methyl ester Proteins 0.000 claims 2
- VXGABWCSZZWXPC-UHFFFAOYSA-N sarcosine methyl ester hydrochloride Natural products CNCC(=O)OC VXGABWCSZZWXPC-UHFFFAOYSA-N 0.000 claims 2
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 229940067621 aminobutyrate Drugs 0.000 claims 1
- JHLHNYVMZCADTC-LOSJGSFVSA-N asimadoline Chemical compound C([C@@H](N(C)C(=O)C(C=1C=CC=CC=1)C=1C=CC=CC=1)C=1C=CC=CC=1)N1CC[C@H](O)C1 JHLHNYVMZCADTC-LOSJGSFVSA-N 0.000 claims 1
- 210000004195 gingiva Anatomy 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 210000004013 groin Anatomy 0.000 claims 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342382P | 2016-05-27 | 2016-05-27 | |
| US62/342,382 | 2016-05-27 | ||
| PCT/US2017/027458 WO2017204918A1 (en) | 2016-05-27 | 2017-04-13 | Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid a |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020077140A Division JP2020111620A (ja) | 2016-05-27 | 2020-04-24 | リポ多糖およびリピドａの阻害のためのミエロペルオキシダーゼ組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515881A JP2019515881A (ja) | 2019-06-13 |
| JP2019515881A5 true JP2019515881A5 (enExample) | 2019-10-24 |
| JP6713546B2 JP6713546B2 (ja) | 2020-06-24 |
Family
ID=60411564
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549315A Active JP6713546B2 (ja) | 2016-05-27 | 2017-04-13 | リポ多糖およびリピドａの阻害のためのミエロペルオキシダーゼ組成物および方法 |
| JP2020077140A Withdrawn JP2020111620A (ja) | 2016-05-27 | 2020-04-24 | リポ多糖およびリピドａの阻害のためのミエロペルオキシダーゼ組成物および方法 |
| JP2021139289A Withdrawn JP2021181500A (ja) | 2016-05-27 | 2021-08-27 | リポ多糖およびリピドａの阻害のためのミエロペルオキシダーゼ組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020077140A Withdrawn JP2020111620A (ja) | 2016-05-27 | 2020-04-24 | リポ多糖およびリピドａの阻害のためのミエロペルオキシダーゼ組成物および方法 |
| JP2021139289A Withdrawn JP2021181500A (ja) | 2016-05-27 | 2021-08-27 | リポ多糖およびリピドａの阻害のためのミエロペルオキシダーゼ組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11389514B2 (enExample) |
| EP (1) | EP3463431B1 (enExample) |
| JP (3) | JP6713546B2 (enExample) |
| CN (1) | CN109414485B (enExample) |
| AU (1) | AU2017269582B2 (enExample) |
| CA (1) | CA3022426C (enExample) |
| IL (1) | IL262930B2 (enExample) |
| MX (1) | MX392701B (enExample) |
| WO (1) | WO2017204918A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3106240A1 (en) * | 2018-07-13 | 2020-01-16 | Robert C. Allen | Haloperoxidase compositions and uses thereof |
| WO2022103565A1 (en) * | 2020-11-13 | 2022-05-19 | Exoxemis, Inc. | Myeloperoxidase-containing compositions and uses thereof |
| WO2024126571A1 (en) * | 2022-12-14 | 2024-06-20 | Universite de Bordeaux | Artificial bifunctional enzyme comprising a myeloperoxidase activity and a glucose oxidase activity and applications thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2108387B (en) | 1979-12-28 | 1984-03-21 | Green Cross Corp | A pharmaceutical composition containing myeloperoxidase |
| US5089274A (en) * | 1989-02-14 | 1992-02-18 | Incyte Pharmaceuticals, Inc. | Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders |
| US5622848A (en) * | 1990-05-23 | 1997-04-22 | Medical Discoveries, Inc. | Electrically hydrolyzed salines as microbiocides for in vitro treatment of contaminated fluids containing blood |
| AU663869B2 (en) | 1991-02-21 | 1995-10-26 | Exoxemis, Inc. | Methods and compositions for the treatment of infection and control of flora |
| US5888505A (en) | 1991-02-21 | 1999-03-30 | Eoe, Inc. | Method for selectively inhibiting the growth of microbes using a haloperoxidase-halide-peroxide system |
| US5389369A (en) * | 1991-02-21 | 1995-02-14 | Exoxemis, Inc. | Halo peroxidase containing compositions for killing yeast and sporular microorganisms |
| US5565197A (en) * | 1991-02-21 | 1996-10-15 | Exoxemis, Inc. | Method which utilizes a haloperoxidase composition to inhibit the growth of microorganisms which cause sexually transmitted diseases |
| US8945540B2 (en) * | 2008-05-09 | 2015-02-03 | Exoxemis, Inc. | Compositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof |
| JP2014520853A (ja) * | 2011-07-11 | 2014-08-25 | エクソゼミス，インコーポレイテッド | 好酸球ペルオキシダーゼ組成物およびその使用方法 |
-
2017
- 2017-04-13 US US16/302,449 patent/US11389514B2/en active Active
- 2017-04-13 EP EP17803212.4A patent/EP3463431B1/en active Active
- 2017-04-13 CA CA3022426A patent/CA3022426C/en active Active
- 2017-04-13 MX MX2018013925A patent/MX392701B/es unknown
- 2017-04-13 JP JP2018549315A patent/JP6713546B2/ja active Active
- 2017-04-13 WO PCT/US2017/027458 patent/WO2017204918A1/en not_active Ceased
- 2017-04-13 IL IL262930A patent/IL262930B2/en unknown
- 2017-04-13 CN CN201780032711.9A patent/CN109414485B/zh active Active
- 2017-04-13 AU AU2017269582A patent/AU2017269582B2/en active Active
-
2020
- 2020-04-24 JP JP2020077140A patent/JP2020111620A/ja not_active Withdrawn
-
2021
- 2021-08-27 JP JP2021139289A patent/JP2021181500A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010150428A (ru) | Композиции для усиления антибактериальной активности миелопероксидазы и способы их применения | |
| JP7397830B2 (ja) | 上皮組織におけるバリア欠陥を伴う疾患の予防または治療において使用するための適合溶質または溶質混合物 | |
| HRP20161039T1 (hr) | Deuterirani derivati kateholamina i lijekovi koji sadrže navedene spojeve | |
| US20060074058A1 (en) | Combination of dpp iv inhibitor and a cardiovascular compound | |
| US7645796B2 (en) | Amino acid composition promoting collagen synthesis | |
| JP2020111620A5 (enExample) | ||
| JP2019515881A5 (enExample) | ||
| WO2008081582A1 (ja) | 容器詰飲料 | |
| CA2177195A1 (en) | Method and composition for treating renal failure | |
| EA200800147A1 (ru) | Способ получения олмесартан медоксомила | |
| US20050159488A1 (en) | D-serine transport antagonist for treating psychosis | |
| WO2008149035A3 (fr) | Nouveau principe actif dans la cicatrisation et son utilisation | |
| JP2011523626A5 (enExample) | ||
| ATE557096T1 (de) | L-tryptophan produzierendes bakterium und verfahren zur produktion von l-tryptophan | |
| RU2009126763A (ru) | Лечение общих расстройств развития | |
| EP1849466B8 (en) | Infusion fluid for treating anemia in dialysis patients | |
| JPS568312A (en) | Amino acid pharmaceutical preparation | |
| FR2883873A1 (fr) | Inhibiteurs d'age | |
| JP2006524182A5 (enExample) | ||
| ATE272399T1 (de) | Zusammensetzungen aus aminosäuren zur behandlung von herzinsuffizienz | |
| WO2009005798A3 (en) | Antifungal formulation and method of preparation | |
| AU685585B2 (en) | Analgesic activity enhancer | |
| ATE487390T1 (de) | Proteinzusammensetzung zur behandlung eines physiologisch bedingten, klinisch unauffälligen proteinmehrbedarfs | |
| Gillissen et al. | Modulation of antimicrobial effects of beta-lactams by amino acids in vitro | |
| JPH02121928A (ja) | Ｌ−チロシンのジペプチドを含有する栄養輸液組成物 |